Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation

Pediatr Transplant. 2024 Mar;28(2):e14707. doi: 10.1111/petr.14707.

Abstract

Epstein-Barr Virus (EBV) is a ubiquitous herpes type virus that is associated with post-transplant lymphoproliferative disorder (PTLD). Usual management includes reduction or cessation of immunosuppression and in some cases chemotherapy including rituximab. However, limited therapies are available if PTLD is refractory to rituximab. Several clinical trials have investigated the use of EBV-directed T cells in rituximab-refractory patients; however, data regarding response is scarce and inconclusive. Herein, we describe a patient with EBV-PTLD refractory to rituximab after orthotopic heart transplantation (OHT) requiring EBV-directed T-cell therapy. This article aims to highlight the unique and aggressive clinical presentation and progression of PTLD with utilization of EBV-directed T-cell therapy for management and associated pitfalls.

Keywords: Epstein-Barr virus; PTLD; cardiac transplantation; rejection; rituximab.

Publication types

  • Case Reports

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Child, Preschool
  • Epstein-Barr Virus Infections* / drug therapy
  • Epstein-Barr Virus Infections* / therapy
  • Heart Transplantation*
  • Hematopoietic Stem Cell Transplantation*
  • Herpesvirus 4, Human
  • Humans
  • Lymphoproliferative Disorders* / diagnosis
  • Lymphoproliferative Disorders* / etiology
  • Lymphoproliferative Disorders* / therapy
  • Rituximab / therapeutic use

Substances

  • Rituximab